; (H) the number of servicemembers who suffered a non-fatal overdose in which naloxone was administered; (I) the number of servicemembers referred to medical treatment, including medication treatment for opioid use disorder, following a non-fatal overdose; (J) of the servicemembers identified in subparagraph (I), the number of servicemembers who engaged in such medical treatment; (K) the number of servicemembers referred, including by self-referral, to medical treatment, including medication treatment for opioid use disorder; (L) with respect to each servicemember identified in subparagraph (K), whether the servicemember was referred after a positive drug test and the source of such referral; (M) of the servicemembers identified in subparagraph (K), the number of servicemembers who engaged in such medical treatment; and (N) the number of intentional overdoses. (5) An analysis of discernable patterns in fatal and non-fatal overdoses of servicemembers, and existing or anticipated responses to such patterns by the Secretary of Defense. (6) A description of existing or anticipated response efforts to fatal and non-fatal overdoses at military bases that have rates of fatal overdoses that exceed the average rate of fatal overdoses in the United States. (7) The number of servicemembers who are in recovery or currently taking a prescription medication for opioid use disorder. (8) The number of military family members of servicemembers who receive substance use disorder treatment at a medical facility of the Department of Defense. (9) An assessment of the availability of substance use disorder treatment for servicemembers who— (A) transferred military bases